|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
18 Years and older
|
|
gptkbp:clinicalTrialPhase
|
Phase 2
|
|
gptkbp:completedIn
|
October 2020
|
|
gptkbp:conditionStudied
|
Multiple Myeloma
|
|
gptkbp:enrollment
|
85
|
|
gptkbp:gender
|
All
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NCT03013101
|
|
gptkbp:intervention
|
gptkb:Dexamethasone
gptkb:Daratumumab
Carfilzomib
|
|
gptkbp:location
|
gptkb:France
gptkb:Germany
gptkb:Italy
gptkb:Netherlands
gptkb:Spain
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:officialName
|
A Study of Daratumumab, Carfilzomib, and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
|
|
gptkbp:primaryCompletionDate
|
October 2020
|
|
gptkbp:result
|
Overall Response Rate
|
|
gptkbp:secondaryOutcome
|
Overall Survival
Progression-Free Survival
Duration of Response
|
|
gptkbp:sponsor
|
Janssen Research & Development, LLC
|
|
gptkbp:startDate
|
January 2017
|
|
gptkbp:status
|
Completed
|
|
gptkbp:studyIdentifier
|
gptkb:NCT03013101
|
|
gptkbp:studyType
|
Interventional
|
|
gptkbp:bfsParent
|
gptkb:Toripalimab
|
|
gptkbp:bfsLayer
|
7
|